LIVIVO - Search results -

Search results

Result 1 - 10 of total 56

Search options

Article ; Online: Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology.

Hampson, Ian N

2022 Volume 14, Issue 4

Abstract: Vaccination programs with the current prophylactic HPV vaccines started in most countries around 2008 with introduction of the bivalent Cervarix HPV16/18 vaccine, rapidly followed by Gardasil (HPV6/11/16/18) and, finally, Gardasil 9 (HPV6/11/16/18/31/33/ ... ...

Abstract	Vaccination programs with the current prophylactic HPV vaccines started in most countries around 2008 with introduction of the bivalent Cervarix HPV16/18 vaccine, rapidly followed by Gardasil (HPV6/11/16/18) and, finally, Gardasil 9 (HPV6/11/16/18/31/33/45/52/58), from 2015. Many studies have now confirmed their ability to prevent infection with vaccine-covered HPV types, and the subsequent development of either genital warts and/or cervical neoplasia, although this is clearly more effective in younger women vaccinated prior to sexual debut. Most notably, reductions in the prevalence of vaccine-covered HPV types were also observed in unvaccinated women at the same geographical location, presumably by sexual dissemination of these changes, between vaccinated and unvaccinated women. Furthermore, there are several studies that have demonstrated vaccine-associated HPV type-replacement, where vaccine-covered, high-risk HPV types are replaced by high-risk HPV types not covered by the vaccines, and these changes were also observed in vaccinated and unvaccinated women in the same study population. In light of these observations, it is not entirely clear what effects vaccine-associated HPV type-replacement will have, particularly in older, unvaccinated women.
MeSH term(s)	Aged ; Female ; Human papillomavirus 16 ; Human papillomavirus 18 ; Humans ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/prevention & control ; Papillomavirus Vaccines ; Prevalence ; Uterine Cervical Neoplasms/epidemiology ; Uterine Cervical Neoplasms/prevention & control
Chemical Substances	Papillomavirus Vaccines
Language	English
Publishing date	2022-04-05
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v14040757
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Potential Effects of Human Papillomavirus Type Substitution, Superinfection Exclusion and Latency on the Efficacy of the Current L1 Prophylactic Vaccines.

Hampson, Ian N / Oliver, Anthony W / Hampson, Lynne

Viruses

2020 Volume 13, Issue 1

Abstract: There are >200 different types of human papilloma virus (HPV) of which >51 infect genital epithelium, with the ~14 of these classed as high-risk being more commonly associated with cervical cancer. During development of the disease, high-risk types have ... ...

Abstract	There are >200 different types of human papilloma virus (HPV) of which >51 infect genital epithelium, with the ~14 of these classed as high-risk being more commonly associated with cervical cancer. During development of the disease, high-risk types have an increased tendency to develop a truncated non-replicative life cycle, whereas low-risk, non-cancer-associated HPV types are either asymptomatic or cause benign lesions completing their full replicative life cycle. HPVs can also be present as non-replicative so-called "latent" infections and they can also show superinfection exclusion, where cells with pre-existing infections with one type cannot be infected with a different HPV type. Thus, the HPV repertoire and replication status present in an individual can form a complex dynamic meta-community which changes with respect to both time and exposure to different HPV types. In light of these considerations, it is not clear how current prophylactic HPV vaccines will affect this system and the potential for iatrogenic outcomes is discussed in light of recent outcome data.
MeSH term(s)	Capsid Proteins/immunology ; Female ; Humans ; Incidence ; Neoplasms/etiology ; Oncogene Proteins, Viral/immunology ; Papillomaviridae/classification ; Papillomaviridae/physiology ; Papillomavirus Infections/complications ; Papillomavirus Infections/pathology ; Papillomavirus Infections/prevention & control ; Papillomavirus Infections/virology ; Papillomavirus Vaccines/immunology ; Prevalence ; Squamous Intraepithelial Lesions of the Cervix/etiology ; Squamous Intraepithelial Lesions of the Cervix/pathology ; Superinfection/virology ; Vaccination ; Virus Latency/immunology ; Virus Replication
Chemical Substances	Capsid Proteins ; HPV L1 protein, Human papillomavirus ; Oncogene Proteins, Viral ; Papillomavirus Vaccines
Language	English
Publishing date	2020-12-24
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v13010022
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia.

Hampson, Lynne / Martin-Hirsch, Pierre / Hampson, Ian N

Expert opinion on investigational drugs

2015 Volume 24, Issue 12, Page(s) 1529–1537

Abstract: Introduction: High-risk HPV (HR-HPV) related invasive cervical cancer (ICC) causes >270,000 deaths per annum world-wide with over 85% of these occurring in low-resource countries. Ablative and excisional treatment modalities are restricted for use with ... ...

Abstract	Introduction: High-risk HPV (HR-HPV) related invasive cervical cancer (ICC) causes >270,000 deaths per annum world-wide with over 85% of these occurring in low-resource countries. Ablative and excisional treatment modalities are restricted for use with high-grade pre-cancerous cervical disease with HPV infection and low-grade dysplasia mostly managed by a watch-and-wait policy. Areas covered: Various pharmacological approaches have been investigated as non-destructive alternatives for the treatment of HR-HPV infection and associated dysplasia. These are discussed dealing with efficacy, ease-of-use (physician or self-applied), systemic or locally applied, side-effects, cost and risks. The main focus is the perceived impact on current clinical practice of a self-applied, effective and safe pharmacological anti-HPV treatment. Expert opinion: Current prophylactic HPV vaccines are expensive, HPV type restricted and have little effect in already infected women. Therapeutic vaccines are under development but are also HPV type-restricted. At present, the developed nations use national cytology screening and surgical procedures to treat only women identified with HPV-related high-grade dysplastic disease. However, since HPV testing is rapidly replacing cytology as the test-of-choice, a suitable topically-applied and low-cost antiviral treatment could be an ideal solution for treatment of HPV infection per se with test-of-cure carried out by repeat HPV testing. Cytology would only then be necessary for women who remained HPV positive. Although of significant benefit in the developed countries, combining such a treatment with self-sampled HPV testing could revolutionise the management of this disease in the developing world which lack both the infrastructure and resources to establish national cytology screening programs.
MeSH term(s)	Animals ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Cervical Intraepithelial Neoplasia/complications ; Cervical Intraepithelial Neoplasia/drug therapy ; Cervical Intraepithelial Neoplasia/virology ; Drug Design ; Drugs, Investigational/administration & dosage ; Drugs, Investigational/adverse effects ; Drugs, Investigational/therapeutic use ; Female ; Humans ; Mass Screening/methods ; Papillomaviridae/isolation & purification ; Papillomavirus Infections/complications ; Papillomavirus Infections/drug therapy ; Papillomavirus Vaccines/administration & dosage ; Uterine Cervical Neoplasms/epidemiology ; Uterine Cervical Neoplasms/prevention & control ; Uterine Cervical Neoplasms/virology
Chemical Substances	Antiviral Agents ; Drugs, Investigational ; Papillomavirus Vaccines
Keywords	covid19
Language	English
Publishing date	2015
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1182884-5
ISSN	1744-7658 ; 0967-8298 ; 1354-3784
ISSN (online)	1744-7658
ISSN	0967-8298 ; 1354-3784
DOI	10.1517/13543784.2015.1099628
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3739: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Using HIV drugs to target human papilloma virus.

Hampson, Lynne / Oliver, Anthony W / Hampson, Ian N

Expert review of anti-infective therapy

2014 Volume 12, Issue 9, Page(s) 1021–1023

Abstract: Over the past decade it has been demonstrated that HIV protease inhibitors have various off-target activities that has enabled them to be repositioned as treatments for a range of other pathologies. Human papilloma virus and related malignancies have ... ...

Abstract	Over the past decade it has been demonstrated that HIV protease inhibitors have various off-target activities that has enabled them to be repositioned as treatments for a range of other pathologies. Human papilloma virus and related malignancies have been shown to be susceptible to these agents and current progress with this indication is summarized here together with a discussion of the rationale for the off-target effects of these compounds.
MeSH term(s)	Alphapapillomavirus/drug effects ; Drug Repositioning ; HIV Protease Inhibitors/administration & dosage ; HIV Protease Inhibitors/therapeutic use ; Humans ; Off-Label Use ; Papillomavirus Infections/drug therapy ; Papillomavirus Infections/virology
Chemical Substances	HIV Protease Inhibitors
Language	English
Publishing date	2014-09
Publishing country	England
Document type	Editorial
ZDB-ID	2181279-2
ISSN	1744-8336 ; 1478-7210
ISSN (online)	1744-8336
ISSN	1478-7210
DOI	10.1586/14787210.2014.950229
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6106: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Nanomicellar Curcumin Supplementation Improves the Clinical Manifestations of HAM/TSP Patients.

Mohammadi, Asadollah / Yazdi, Shadi Zamanian / Poursina, Zohreh / Hampson, Ian N / Vakili, Veda / Sahebkar, Amirhossein / Akbarien, Mohammad Mehdi / Rahimi, Hamidreza / Vakili, Rosita / Boostani, Reza / Rafatpanah, Houshang

Advances in experimental medicine and biology

2022 Volume 1328, Page(s) 347–359

Abstract: Background: HTLV-1 infection causes a chronic, progressive, demyelinating, neuroinflammatory disease called HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Treatment of HAM/TSP patients which have high levels of proviral load and ... ...

Abstract	Background: HTLV-1 infection causes a chronic, progressive, demyelinating, neuroinflammatory disease called HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Treatment of HAM/TSP patients which have high levels of proviral load and pro-inflammatory markers is a challenge for clinicians. Therefore, we aimed to investigate the immunomodulatory, anti-inflammatory, and antiviral effects of curcumin in HAM/TSP patients. Methods: In this study, 20 newly diagnosed HAM/TSP patients (2 men and 18 women) were enrolled and evaluated for clinical symptoms, HTLV-1 proviral load, Tax and HBZ expression, neopterin serum concentration, and complete blood count (CBC) before and 12 weeks after treatment with nanomicellar curcumin (80 mg/day, orally). Results: Clinical symptoms such as the mean Osame Motor Disability Score and Ashworth Spasticity Scale Score were significantly improved after the treatment (P = 0.001 and P = 0.001). Sensory symptoms such as pain and paresthesia were significantly decreased in all of the patients (P = 0.001). Furthermore, urinary disorders, including urinary frequency, incontinence, and the feeling of incomplete bladder emptying, were significantly improved (P = 0.001, P = 0.003, and P = 0.03). However, the mean HTLV-1 proviral load (P = 0.97) and CBC were similar, whereas Tax, HBZ, and neopterin levels tend to increase after the treatment (P = 0.004, P = 0.08, and P = 0.04). Conclusion: Results suggest that curcumin can safely improve the clinical symptoms of HAM/TSP patients but has no observable positive effects on the HTLV-1 proviral load, Tax, and HBZ expression. Therefore, prolonged use or the use of curcumin with antiviral agents in addition to clinical signs and symptoms can reduce the HTLV-1 proviral load and the expression of functional viral factors such as Tax and HBZ.
MeSH term(s)	Basic-Leucine Zipper Transcription Factors ; Curcumin/therapeutic use ; Dietary Supplements ; Disabled Persons ; Female ; Humans ; Male ; Motor Disorders ; Neuroinflammatory Diseases ; Paraparesis, Tropical Spastic/drug therapy ; Retroviridae Proteins ; Viral Load
Chemical Substances	Basic-Leucine Zipper Transcription Factors ; Retroviridae Proteins ; Curcumin (IT942ZTH98)
Language	English
Publishing date	2022-01-04
Publishing country	United States
Document type	Journal Article
ISSN	2214-8019 ; 0065-2598
ISSN (online)	2214-8019
ISSN	0065-2598
DOI	10.1007/978-3-030-73234-9_22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Targeting activated Rho proteins: a new approach for treatment of HPV and other virus-related cancers?

Hampson, Ian N / Oliver, Anthony W / Hampson, Lynne

Expert review of anticancer therapy

2011 Volume 11, Issue 7, Page(s) 973–976

MeSH term(s)	Humans ; Molecular Targeted Therapy ; Neoplasms/metabolism ; Neoplasms/therapy ; Neoplasms/virology ; Papillomaviridae ; Papillomavirus Infections/metabolism ; Papillomavirus Infections/prevention & control ; Papillomavirus Infections/therapy ; rho GTP-Binding Proteins/physiology
Chemical Substances	rho GTP-Binding Proteins (EC 3.6.5.2)
Language	English
Publishing date	2011-07
Publishing country	England
Document type	Editorial
ZDB-ID	2112544-2
ISSN	1744-8328 ; 1473-7140
ISSN (online)	1744-8328
ISSN	1473-7140
DOI	10.1586/era.11.86
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5907: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Analysis of the Prevalence of HTLV-1 Proviral DNA in Cervical Smears and Carcinomas from HIV Positive and Negative Kenyan Women.

He, Xiaotong / Maranga, Innocent O / Oliver, Anthony W / Gichangi, Peter / Hampson, Lynne / Hampson, Ian N

Viruses

2016 Volume 8, Issue 9

Abstract: The oncogenic retrovirus human T-cell lymphotropic virus type 1 (HTLV-1) is endemic in some countries although its prevalence and relationship with other sexually transmitted infections in Sub-Saharan Africa is largely unknown. A novel endpoint PCR ... ...

Abstract	The oncogenic retrovirus human T-cell lymphotropic virus type 1 (HTLV-1) is endemic in some countries although its prevalence and relationship with other sexually transmitted infections in Sub-Saharan Africa is largely unknown. A novel endpoint PCR method was used to analyse the prevalence of HTLV-1 proviral DNA in genomic DNA extracted from liquid based cytology (LBC) cervical smears and invasive cervical carcinomas (ICCs) obtained from human immunodeficiency virus-positive (HIV+ve) and HIV-negative (HIV-ve) Kenyan women. Patient sociodemographic details were recorded by structured questionnaire and these data analysed with respect to HIV status, human papillomavirus (HPV) type (Papilocheck(®)) and cytology. This showed 22/113 (19.5%) of LBC's from HIV+ve patients were positive for HTLV-1 compared to 4/111 (3.6%) of those from HIV-ve women (p = 0.0002; odds ratio (OR) = 6.42 (2.07-26.56)). Only 1/37 (2.7%) of HIV+ve and none of the 44 HIV-ve ICC samples were positive for HTLV-1. There was also a significant correlation between HTLV-1 infection, numbers of sexual partners (p < 0.05) and smoking (p < 0.01). Using this unique method, these data suggest an unexpectedly high prevalence of HTLV-1 DNA in HIV+ve women in this geographical location. However, the low level of HTLV-1 detected in HIV+ve ICC samples was unexpected and the reasons for this are unclear.
MeSH term(s)	Adult ; Carcinoma/complications ; Cross-Sectional Studies ; DNA, Viral/genetics ; DNA, Viral/isolation & purification ; Female ; HIV Infections/complications ; HTLV-I Infections/epidemiology ; Humans ; Kenya/epidemiology ; Middle Aged ; Proviruses/genetics ; Proviruses/isolation & purification ; Uterine Cervical Neoplasms/complications ; Vaginal Smears ; Young Adult
Chemical Substances	DNA, Viral
Language	English
Publishing date	2016-09-05
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v8090245
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Increased prevalence of JC polyomavirus in cervical carcinomas from women infected with HIV.

Alosaimi, Bandar / Hampson, Lynne / He, Xiaotong / Maranga, Innocent O / Oliver, Anthony W / Hampson, Ian N

Journal of medical virology

2014 Volume 86, Issue 4, Page(s) 672–677

Abstract: Although subclinical persistent infections with the human polyomaviruses BKV and JCV are ubiquitous worldwide, these are known to vary in relation to diseases present and geographical location. DNAs from 220 cervical smears and 109 invasive cervical ... ...

Abstract	Although subclinical persistent infections with the human polyomaviruses BKV and JCV are ubiquitous worldwide, these are known to vary in relation to diseases present and geographical location. DNAs from 220 cervical smears and 109 invasive cervical carcinomas obtained from HIV positive and HIV negative Kenyan women of known HPV status were analyzed by nested endpoint PCR for BKV and JCV. BKV-JCV DNA was detected in 5/105 (4.7%) of cervical smears and in 6/37 (16%) of cervical carcinomas from women infected with HIV whereas 9/115 (7.8%) of the cervical smears and 4/72 (5.5%) of the carcinomas were positive in HIV negative women. Nested PCR showed that all 24 samples were positive for JCV and not BKV. JCV was not more prevalent in either HPV positive (P = 0.438) or HPV negative women (P = 0.392). However, 37% of carcinomas and smears which were positive for JCV were also positive for a "high-risk" oncogenic HPV. Comparison of the incidence of JCV in cervical smears and cervical carcinomas showed a ∼3-fold increase in samples from HIV positive women with cervical carcinoma (P = 0.025) whereas no significant difference was found between cervical smears and cervical carcinomas from HIV negative women (P = 0.553). These results suggest that JCV may combine with high-risk HPV infection in women infected with HIV to influence the rate of progression to invasive cervical carcinoma.
MeSH term(s)	Adult ; Alphapapillomavirus/genetics ; Alphapapillomavirus/pathogenicity ; BK Virus/genetics ; BK Virus/pathogenicity ; DNA, Viral/analysis ; Female ; HIV Infections/epidemiology ; HIV Infections/virology ; Humans ; JC Virus/genetics ; JC Virus/pathogenicity ; Middle Aged ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/virology ; Polyomavirus Infections/epidemiology ; Tumor Virus Infections/epidemiology ; Uterine Cervical Neoplasms/epidemiology ; Uterine Cervical Neoplasms/virology ; Vaginal Smears ; Young Adult
Chemical Substances	DNA, Viral
Language	English
Publishing date	2014-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.23868
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Silver nanoparticles exhibit size-dependent differential toxicity and induce expression of syncytin-1 in FA-AML1 and MOLT-4 leukaemia cell lines.

Alqahtani, Sultan / Promtong, Pawika / Oliver, Anthony W / He, Xiaotong T / Walker, Thomas D / Povey, Andrew / Hampson, Lynne / Hampson, Ian N

Mutagenesis

2016 Volume 31, Issue 6, Page(s) 695–702

Abstract: Human endogenous retrovirus (HERV) sequences make up ~8% of the human genome and increased expression of some HERV proteins has been observed in various pathologies including leukaemia and multiple sclerosis. However, little is known about the function ... ...

Abstract	Human endogenous retrovirus (HERV) sequences make up ~8% of the human genome and increased expression of some HERV proteins has been observed in various pathologies including leukaemia and multiple sclerosis. However, little is known about the function of these HERV proteins or environmental factors which regulate their expression. Silver nanoparticles (AgNPs) are used very extensively as antimicrobials and antivirals in numerous consumer products although their effect on the expression of HERV gene products is unknown. Cell proliferation and cell toxicity assays were carried out on human acute T lymphoblastic leukaemia (MOLT-4) and Fanconi anaemia associated acute myeloid leukaemia (FA-AML1) cells treated with two different sizes of AgNPs (7nm and 50nm diameter). Reverse-transcriptase polymerase chain reaction and western blotting were then used to the assess expression of HERV-W syncytin-1 mRNA and protein in these cells. FA-AML1 cells were more sensitive overall than MOLT-4 to treatment with the smaller 7nm sized AgNp's being the most toxic in these cells. MOLT-4 cell were more resistant and showed no evidence of differential toxicity to the different sized particles. Syncytin-1 mRNA and protein were induced by both 7 and 50nm AgNPs in both cell types yet with different kinetics. In summary, the observation that AgNPs induce expression of syncytin-1 in FA-AML1 and MOLT-4 cells at doses as little as 5 µg/ml is grounds for concern since this protein is up-regulated in both malignant and neurodegenerative diseases. Considering the widespread use of AgNPs in the environment it is clear that their ability to induce syncytin-1 should be investigated further in other cell types.
MeSH term(s)	Cell Proliferation ; Endogenous Retroviruses/metabolism ; Fanconi Anemia/complications ; Gene Expression Regulation, Leukemic ; Gene Products, env/drug effects ; Gene Products, env/genetics ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/etiology ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/physiopathology ; Leukemia, T-Cell/drug therapy ; Leukemia, T-Cell/metabolism ; Leukemia, T-Cell/physiopathology ; Metal Nanoparticles/chemistry ; Metal Nanoparticles/toxicity ; Pregnancy Proteins/drug effects ; Pregnancy Proteins/genetics ; RNA, Messenger ; Silver/pharmacology ; Silver/toxicity ; Up-Regulation
Chemical Substances	Gene Products, env ; Pregnancy Proteins ; RNA, Messenger ; syncytin ; Silver (3M4G523W1G)
Language	English
Publishing date	2016-11
Publishing country	England
Document type	Journal Article
ZDB-ID	632903-2
ISSN	1464-3804 ; 0267-8357
ISSN (online)	1464-3804
ISSN	0267-8357
DOI	10.1093/mutage/gew043
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2189: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis.

Megremis, Spyridon / Walker, Thomas D J / He, Xiaotong / O'Sullivan, James / Ollier, William E R / Chinoy, Hector / Pendleton, Neil / Payton, Antony / Hampson, Lynne / Hampson, Ian / Lamb, Janine A

Communications biology

2021 Volume 4, Issue 1, Page(s) 419

Abstract: We investigate the accumulated microbial and autoantigen antibody repertoire in adult-onset dermatomyositis patients sero-positive for TIF1γ (TRIM33) autoantibodies. We use an untargeted high-throughput approach which combines immunoglobulin disease- ... ...

Abstract	We investigate the accumulated microbial and autoantigen antibody repertoire in adult-onset dermatomyositis patients sero-positive for TIF1γ (TRIM33) autoantibodies. We use an untargeted high-throughput approach which combines immunoglobulin disease-specific epitope-enrichment and identification of microbial and human antigens. We observe antibodies recognizing a wider repertoire of microbial antigens in dermatomyositis. Antibodies recognizing viruses and Poxviridae family species are significantly enriched. The identified autoantibodies recognise a large portion of the human proteome, including interferon regulated proteins; these proteins cluster in specific biological processes. In addition to TRIM33, we identify autoantibodies against eleven further TRIM proteins, including TRIM21. Some of these TRIM proteins share epitope homology with specific viral species including poxviruses. Our data suggest antibody accumulation in dermatomyositis against an expanded diversity of microbial and human proteins and evidence of non-random targeting of specific signalling pathways. Our findings indicate that molecular mimicry and epitope spreading events may play a role in dermatomyositis pathogenesis.
MeSH term(s)	Autoantibodies/genetics ; Autoantibodies/immunology ; Dermatomyositis/genetics ; Dermatomyositis/immunology ; Humans ; Transcription Factors/immunology
Chemical Substances	Autoantibodies ; TRIM33 protein, human ; Transcription Factors
Language	English
Publishing date	2021-03-26
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2399-3642
ISSN (online)	2399-3642
DOI	10.1038/s42003-021-01932-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED